Emma Andrus, Assistant Editor

Data presented in a poster presentation at the 2023 World Congress of Dermatology meeting in Singapore showed significant improvements to patient quality of life.

Pediococcus acidilactici demonstrated significant clinical efficacy and potential in treating hyperpigmentation.

Pediatric patients with moderate to severe eczema demonstrated an increased risk of experiencing the food allergy.

As we have surpassed the halfway mark of 2023, Dermatology Times is spotlighting vitiligo coverage and news from the first half of year.

The authorization comes just over 2 months after the drug’s approval in the European Union.

Trained immunity may act as an enhancer and continuous trigger in the disease’s pathogenesis.

The combination of therapies achieved significant efficacy, with researchers noting a higher cure rate than is evident in other therapies for the condition.

The device is now the first of its kind to become available to pediatric patients.

Five expert dermatology clinicians discuss the changing landscape of plaque psoriasis treatments and research for adult patients.

If you weren’t able to attend the 2023 Society of Dermatology Physician Assistants (SDPA) Annual Summer Dermatology Conference or want to review our latest coverage and interviews, our full recap has you covered.

Click here to answer today's poll.

Catch up on coverage from the fourth and final day of the 2023 SDPA Annual Summer Dermatology Conference.

Want to reminisce on your time on Boston? View our conference photo gallery below.

As SDPA summer sessions have concluded, Arash Mostaghimi, MD, MPA, MPH, delves into what lies ahead in the dermatology industry—including the importance of collaboration between physicians and PAs.

Orit Markowitz, MD, discusses the future of non-invasive lasers in removing skin cancer and cancerous lesions, ultimately allowing patients to leave the practice without a bandaid.

Jane Mast, PhD, DMSc, MPAS, discusses empathetic care in hidradenitis suppurativa and the importance of supporting patients with HS in every step of their journey with the condition.

Arash Mostaghimi, MD, MPA, MPH, provides a comprehensive overview of his SDPA conference sessions, "Understanding the Pathology Report and Basic Biopsies," "Beyond the H&E," and "Alopecia: Treating Challenging Cases."

The drug also demonstrated efficacy in improving sleep quality and reducing sleep disruption.

In recognition of World Vitiligo Day, the Dermatology Times team is spotlighting advances and educational opportunities for the condition.

Catch up on coverage from the third day of the 2023 SDPA Annual Summer Dermatology Conference.

Ahmad Amin, MD, FAAD, reviews biologic selection in patients with psoriatic disease.

Megan Noe, MD, MPH, MSCE, reviews best practices for treating patients with cutaneous blisters and managing chronic bullous disorders.

Joslyn Kirby, MD, discusses the importance of awareness and recognition in hidradenitis suppurativa from a clinician and patient perspective.

A poster presented at the SDPA Annual Summer Dermatology Conference revealed the abrocitinib did not have a significant impact on adolescent immune responses to Tdap vaccination.

With bimekizumab, the conservative imputation method led to higher response rates, achieved endpoints, and blocked IL-17A and IL-17F.

Catch up on coverage from the second day of the 2023 SDPA Annual Summer Dermatology Conference.

Over 24 weeks, dupilumab demonstrated efficacy in patients with chronic spontaneous urticaria.

Renata Block, MMS, PA-C, talks about the role of physician assistants in dermatology and related organizations in supporting PAs.

In the case of one patient, researchers found that topical tapinarof cream demonstrated therapeutic efficacy in nonulcerated necrobiosis lipoidica.

John Barbieri, MD, MBA, FAAD, discusses his SDPA Annual Summer Dermatology Conference sessions, "Foundational Tools for Acne and Rosacea Management," and "Neutraceuticals and Cosmeceuticals: Which to Choose?"